GlassScriptPhysician profile
Manasa Ujire
NPI 1063679413
$3,771.54
in general payments reported to CMS, 2019-2025
19 companies · $730 in 2025
The $730 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $720 · 2020: $514 · 2021: $316 · 2022: $229 · 2023: $421 · 2024: $842 · 2025: $730.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,913 · Education: $78.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,913.49 |
| Education | $78.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $1,131.64 | 2019-2025 | Veltassa |
| Alexion Pharmaceuticals, INC. | $436.89 | 2024-2025 | Ultomiris, Soliris |
| Veloxis Pharmaceuticals, INC. | $409.56 | 2019-2025 | Envarsus |
| Astrazeneca Pharmaceuticals LP | $261.76 | 2019-2025 | Lokelma, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $233.60 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $223.14 | 2021-2024 | Livtencity |
| Merck Sharp & Dohme LLC | $202.90 | 2024-2025 | Prevymis |
| Mallinckrodt Hospital Products INC. | $184.72 | 2020-2025 | Terlivaz, Acthar |
| Calliditas Therapeutics US INC. | $142.78 | 2024 | |
| Eurofins Viracor, LLC | $121.71 | 2025 | |
| Ardelyx, INC. | $120.29 | 2024 | Xphozah 30 Mg |
| Genzyme Corporation | $99.13 | 2019 | |
| Ani Pharmaceuticals, INC. | $67.52 | 2022-2023 | Purified Cortrophin Gel |
| Novartis Pharmaceuticals Corporation | $46.88 | 2025 | |
| Acera Surgical, INC. | $23.25 | 2025 | Restrata Wound Matrix |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $19.39 | 2025 | Tavneos |
| One Lambda, INC. | $16.53 | 2025 | |
| Kci USA, INC. | $15.15 | 2022 | |
| Dova Pharmaceuticals | $14.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manasa Ujire listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.